» Articles » PMID: 15140012

The Dark Phase Improves Genetic Discrimination for Some High Throughput Mouse Behavioral Phenotyping

Overview
Date 2004 May 14
PMID 15140012
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Dark-phase testing has previously been shown by others to improve the outcome of some 'classical' behavior test situations. However, the importance of such ethological correctness and the effect of the light/dark cycle on high throughput behavioral testing situations such as 'mutant vs. wild type' and 'screening', are less or unknown, respectively. These testing situations differ from the 'classical' in that they are designed primarily to discriminate between genetically different mice rather than provide a detailed assessment of ability or psychosocial state. Here we test the hypotheses that dark-phase testing affects the outcome of high throughput behavioral tests and that dark-phase testing improves discrimination between genetically distinct mice (C57BL/6J, 129S1/SvImJ and B6129F1) using high throughput behavioral tests. Our results demonstrate that, although all successful tests showed some effect of phase, only the SHIRPA primary screen, open-field test and motor learning on the rotarod showed improved strain discrimination in the dark phase. Surprisingly, the social interaction test did not show a clear benefit to either phase, and interestingly, the tail-flick test discriminated strains better in the light phase. However, since the preponderance of our data shows that dark-phase testing improves, or does not affect, strain discrimination, we conclude that for these strains and tests, dark-phase testing provided superior outcomes. If discrimination is not achieved in the dark phase, then light phase-testing would be undertaken.

Citing Articles

Taf1 knockout is lethal in embryonic male mice and heterozygous females show weight and movement disorders.

Crombie E, Korecki A, Cleverley K, Adair B, Cunningham T, Lee W Dis Model Mech. 2024; 17(7).

PMID: 38804708 PMC: 11261634. DOI: 10.1242/dmm.050741.


Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington's disease.

Wilton D, Mastro K, Heller M, Gergits F, Willing C, Fahey J Nat Med. 2023; 29(11):2866-2884.

PMID: 37814059 PMC: 10667107. DOI: 10.1038/s41591-023-02566-3.


Continuous home cage monitoring of activity and sleep in mice during repeated paroxetine treatment and discontinuation.

Collins H, Pinacho R, Tam S, Sharp T, Bannerman D, Peirson S Psychopharmacology (Berl). 2023; 240(11):2403-2418.

PMID: 37584734 PMC: 10593620. DOI: 10.1007/s00213-023-06442-3.


The 5XFAD mouse model of Alzheimer's disease displays age-dependent deficits in habituation to a novel environment.

Smith S, Hopp S Aging Brain. 2023; 3:100078.

PMID: 37333676 PMC: 10275951. DOI: 10.1016/j.nbas.2023.100078.


Early chronic suppression of microglial p38α in a model of Alzheimer's disease does not significantly alter amyloid-associated neuropathology.

Braun D, Frazier H, Davis V, Coleman M, Rogers C, Van Eldik L PLoS One. 2023; 18(5):e0286495.

PMID: 37256881 PMC: 10231773. DOI: 10.1371/journal.pone.0286495.